Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (AVXL): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating fiduciary-duty claims against certain Anavex Life Sciences officers and directors, and is soliciting long-term shareholders to seek corporate reforms, with a federal securities fraud class action also pending for purchasers between November 26, 2025 and August 28, 2026. The underlying allegations stem from the April 30, 2026 termination of former CEO Christopher Missling for cause, followed by a late 10-Q filing and disclosures that internal controls over financial reporting were not effective through June 30, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.